Related Experiment Video
Updated: Jul 16, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
[Lung cancer: targeted therapy]
1Helios-Klinikum Emil von Behring, Lungenklinik Heckeshorn, Pneumologie, Berlin. m.serke@berlin-behring.helios-kliniken.de
Abstract:
An increased understanding of the biology of lung cancer has identified biological targets for rationally designed novel therapies. Most of these targets are components of signalling pathways or metabolic processes. EGFR-tyrosinkinase inhibitors have become standard in second- and thirdline therapy of NSCLC, the anti-VEGF-antibody Avastin combined with first-line chemotherapy showed a significant survival benefit over chemotherapy alone. There are ongoing studies with targeted therapies in all stages of lung cancer. Major advances of these new drugs are their low toxicity and, in part, the oral application.
Insights
Novel lung cancer therapies targeting biological pathways show promise. These targeted drugs, including EGFR-tyrosin kinase inhibitors and Avastin, offer improved outcomes and lower toxicity for non-small cell lung cancer (NSCLC) patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Advances in understanding lung cancer biology have revealed key signaling pathways and metabolic processes as potential therapeutic targets.
- Targeted therapies represent a new frontier in lung cancer treatment, moving beyond traditional chemotherapy.
Purpose of the Study:
- To review the current landscape and impact of novel targeted therapies in lung cancer treatment.
- To highlight the efficacy and safety profiles of emerging lung cancer drugs.
Main Methods:
- Review of recent clinical studies and research on targeted lung cancer therapies.
- Analysis of data on drug efficacy, toxicity, and patient outcomes.
Main Results:
- EGFR-tyrosin kinase inhibitors are established in second- and third-line treatment for non-small cell lung cancer (NSCLC).
- The anti-VEGF antibody Avastin, combined with chemotherapy, significantly improves survival in first-line NSCLC treatment.
- Ongoing trials are investigating targeted therapies across all stages of lung cancer.
Conclusions:
- Targeted therapies offer a promising approach to lung cancer treatment with reduced toxicity.
- The oral administration of some targeted drugs enhances patient convenience and adherence.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...